within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD16_MetforminAndCanagliflozi;

model MetforminAndCanagliflozi
  extends Pharmacolibrary.Drugs.ATC.A.A10BD16;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>MetforminAndCanagliflozin</td></tr><tr><td>ATC code:</td><td>A10BD16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metformin and canagliflozin is a fixed-dose combination medication used for the treatment of type 2 diabetes mellitus in adults. Metformin is a biguanide antihyperglycemic agent primarily used to improve glycemic control by decreasing hepatic glucose production and increasing insulin sensitivity, while canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidney, resulting in increased urinary glucose excretion. This combination is currently approved and marketed for medical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for average healthy adults, as direct pharmacokinetic parameterization of the fixed-dose combination is not available in publication. Parameters for each component are approximated from studies of individual drugs. Estimated for oral administration of metformin (1000 mg) and canagliflozin (300 mg).</p><h4>References</h4><ol><li><p>Wattamwar, T, et al., &amp; Pandita, N (2020). Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1154 122281–None. DOI:<a href=\"https://doi.org/10.1016/j.jchromb.2020.122281\">10.1016/j.jchromb.2020.122281</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32763846/\">https://pubmed.ncbi.nlm.nih.gov/32763846</a></p></li><li><p>Scheen, AJ (2015). Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. <i>Drugs</i> 75(1) 33–59. DOI:<a href=\"https://doi.org/10.1007/s40265-014-0337-y\">10.1007/s40265-014-0337-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25488697/\">https://pubmed.ncbi.nlm.nih.gov/25488697</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MetforminAndCanagliflozi;
